Faster drugs to market
Rearchitect clinical trials
TCS ADD™
Agile and safe clinical trials are key to faster drug development
The need to synthesize data from different sources increases the risk of regulatory non-compliance for pharma companies. As a result, they face an exponential increase in clinical research and development costs, sub-optimal clinical trial execution, and delays in launching new, approved drugs. TCS ADD™ enables digital ecosystems, simplifies data complexity, and drives innovation in clinical trials to bring drugs to market faster.
Highlights
Features
Quicker decision-making with real-time access to data
Faster drug registration with adaptive trial design
Improved data quality with advanced analytics
Unified platform for sites, patients, and regulators
Enabling a time-critical remote consent
TCS helped Roche roll out an eConsent solution
our solutions
A ready-to-use, interoperable metadata-driven AI platform that automates study build, enables robust governance, and rapidly transforms and generates submission-ready datasets
A one-stop, integrated, cloud-deployed, self-service solution that caters to all data management needs of pharma
TCS ADD™ Analytics and Insights platform leverages AI and ML in clinical trials to enable faster study start-ups and achieve targeted study interventions.
Read how TCS ADD™ Connected Clinical Trials, a decentralized clinical trials platform, makes trials patient-centric, site friendly, and digital by default.
TCS ADD™ Safety, an AI platform for pharmacovigilance, can help firms enable audit readiness with transparent algorithms. See how our solution can help you.
Read how the AI platform accelerates drug regulatory compliance that helps improve operational efficiencies and enables taking informed strategic decisions.
In order to accelerate clinical R&D and launch drugs faster to market, it is extremely important that science is complemented with easy-to-implement technology that is powered by artificial intelligence, data-driven smart analytics, and Internet of Things.
